Company intelligence / Profile preview
Proxygen
Vienna, Vienna, Austriaproxygen.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Preclinical
01
Overview
Proxygen has developed a proprietary platform for discovering molecular glue degraders that can target previously undruggable proteins. The company has made significant progress in both internal drug discovery and strategic partnerships with major pharmaceutical companies. No clinical results have been published as of May 2025; programs are preclinical but advancing toward the clinic[3].
- Therapeutic areas
- Oncology
- Modalities
- Molecular glue degraders (small molecules)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Boehringer IngelheimMerck KGaAMerck & Co., Inc. (MSD outside US/Canada)
Beyond the preview
Go deeper on Proxygen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Proxygen.